Their large surface area makes nanoconstructs nearly ideal as a platform for theranostic agents. When compared to small-molecule or biologics, nanoparticles can be synthesized with an excess of sites for conjugation. This allow for the development of multimodal agents that can serve as diagnostic, therapeutic, or both.
Heike Daldrup-Link, Radiology, Stanford University, Stanford, CA, USA
Nanoparticles for MR Imaging have been developing and ferumoxytol has been approved by the FDA as an iron supplement to treat anemia. Radiologists use it off label as a contrast agent for MR Imaging. This presentation will discuss how ferumoxytol distributes in the body, how we can use ferumoxytol to deliver therapeutics, and will touch on intrinsic therapeutic effects of ferumoxytol.
A novel theranostic strategy for MMP-14 expressing glioblastomas impacts survival
Suchismita Mohanty, Stanford University, Stanford, CA, USA
- Challenges in Glioblastoma therapy
- Theranostic nanoparticles: Concept and design
- Matrix metalloproteinase-14 function
- In vivo behavior of theranostic strategy
Ultrasound-triggered micro-to-nano conversion: Exploring porphyrin-bubble theranostic potential beyond the vasculature
Carly Pellow, University of Toronto, Toronto, Canada
- Nanomedicine and the Tumor Microvasculature
- Microbubbles and Ultrasound-Triggered Bio-effects
- Porphyrin Microbubbles
- In vivo protocols and outcomes